Article
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.
Cancer discovery - 1 Feb 2018
Sullivan Ryan J, Infante Jeffrey R, Janku Filip, Wong Deborah Jean Lee, Sosman Jeffrey A, Keedy Vicki, Patel Manish R, Shapiro Geoffrey I, Mier James W, Tolcher Anthony W, Wang-Gillam Andrea, Sznol Mario, Flaherty Keith, Buchbinder Elizabeth, Carvajal Richard D, Varghese Anna M, Lacouture Mario E, Ribas Antoni, Patel Sapna P, DeCrescenzo Gary A, Emery Caroline M, Groover Anna L, Saha Saurabh, Varterasian Mary, Welsch Dean J, Hyman David M, Li Bob T
Abstract excerpt
Ulixertinib (BVD-523) is an ERK1/2 kinase inhibitor with potent preclinical activity in BRAF- and RAS-mutant cell lines. In this multicenter phase I trial (NCT01781429), 135 patients were enrolled to an accelerated 3 + 3 dose-escalation cohort and six distinct dose-expansion cohorts. Dose escalation included 27 patients, dosed from 10 to 900 mg twice daily and established the recommended phase II dose (RP2D) of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.